I'm LongbridgeAI, I can summarize articles.Citi said in a report that the US Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding AKESO (09926.HK) -19.050 (-23.147%) Short selling $666.91M; Ratio 21.836% 's ivonescimab combined with chemotherapy for advanced non-small cell lung cancer (NSCLC) following EGFR-TKI treatment, stating that HARMONi failed to establish sufficient clinical evidence because the statistically significant progression-free survival (PFS) benefit was not accompanied by a statistically significant improvement in overall survival (OS).
The broker believes the HARMONi results may be related to factors such as study design. As the CRL is efficacy-related in nature, there is limited room for resubmission, and focus will shift to other global Phase III studies that may provide clearer OS evidence, with HARMONi-3 being the next key catalyst to watch closely. The broker noted that the FDA's decision will delay potential overseas licensing income and weaken near-term visibility for ivonescimab's commercialization in the US.
As a result, the broker lowered its revenue forecasts for FY2027 and FY2028 by 1% and 1%, respectively, and reduced net profit forecasts by 12% and 3%, respectively. It cut the TP from HKD171 to HKD163 and maintained the "Buy" rating. (ha/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-11-16 12:25.)
